CLINICAL_TRIALS
withdrawal
· 2018-07-30
Clinical Trial Update: Safety and Activity of SNX-5422 Plus Ibrutinib in CLL [Phase 1]
Summary
Phase 1 trial investigating SNX-5422 in combination with ibrutinib in chronic lymphocytic leukemia has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Esanex Inc. | Conditions: Cancer | Phase 1 | Status: WITHDRAWN